These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10433467)

  • 41. Extravasation injuries and emergency suction as treatment.
    Vandeweyer E; Heymans O; Deraemaecker R
    Plast Reconstr Surg; 2000 Jan; 105(1):109-10. PubMed ID: 10626979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reducing the morbidity from extravasation injuries.
    Khan MS; Holmes JD
    Ann Plast Surg; 2002 Jun; 48(6):628-32; discussion 632. PubMed ID: 12055433
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.
    Lee YR; Kang MH; Park HM
    Can Vet J; 2015 Jun; 56(6):571-4. PubMed ID: 26028676
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
    Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Therapeutic activity of epirubicin in malignant melanoma and non-Hodgkin's lymphoma].
    Lopez M; Di Lauro L; Papaldo P; Lazzaro B
    Clin Ter; 1984 Apr; 109(1):31-5. PubMed ID: 6233078
    [No Abstract]   [Full Text] [Related]  

  • 47. [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
    Vasyuk YA; Shkolnik EL; Nesterov VV; Shkolnik LD; Varlan GV
    Kardiologiia; 2016 Dec; 56(12):72-79. PubMed ID: 28290807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [4'-epidoxorubicin].
    Mechl Z
    Cas Lek Cesk; 1985 Jun; 124(24):755-7. PubMed ID: 3860300
    [No Abstract]   [Full Text] [Related]  

  • 49. Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation.
    Arroyo PA; Perez RU; Feijoo MA; Hernandez MA
    J Cancer Res Ther; 2010; 6(4):573-4. PubMed ID: 21358106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation.
    Lawrence HJ; Walsh D; Zapotowski KA; Denham A; Goodnight SH; Gandara DR
    Cancer Chemother Pharmacol; 1989; 23(5):316-8. PubMed ID: 2706738
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CHEMOTHERAPY HAZARDS: ANTHRACYCLINE EXTRAVASATION INTO PLEURAL SPACE.
    Almendra A; Falcão P; Moreira S; Azevedo P
    Port J Card Thorac Vasc Surg; 2022 Apr; 29(1):61-63. PubMed ID: 35471214
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention of extravasation injuries secondary to doxorubicin.
    Linder RM; Upton J
    Postgrad Med; 1985 Mar; 77(4):105-9, 112, 114. PubMed ID: 3975182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does the multidrug-resistance modulator cyclosporin A increase the cardiotoxicity of high-dose anthracycline chemotherapy?
    Eising EG; Gries P; Eggert J; Scheulen ME
    Acta Oncol; 1997; 36(7):735-40. PubMed ID: 9490093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
    Kawai S; Tani M; Okamura J; Ogawa M; Ohashi Y; Monden M; Hayashi S; Inoue J; Kawarada Y; Kusano M; Kubo Y; Kuroda C; Sakata Y; Shimamura Y; Jinno K; Takahashi A; Takayasu K; Tamura K; Nagasue N; Nakanishi Y; Makino M; Masuzawa M; Yumoto Y; Mori T; Oda T
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-38-S6-45. PubMed ID: 9151915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. American symposium looks at new antineoplastic drug.
    Korcok M
    Can Med Assoc J; 1985 Jul; 133(1):66-7. PubMed ID: 3891062
    [No Abstract]   [Full Text] [Related]  

  • 57. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma.
    Nair R; Ramakrishnan G; Nair NN; Saikia TK; Parikh PM; Joshi SR; Soman CS; Mukhadan M; Dinshaw KT; Advani SH
    Cancer; 1998 Jun; 82(11):2282-8. PubMed ID: 9610711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
    Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epirubicin seems to cause venous sclerosis.
    Lennan E; Middleton JM; Luken J
    BMJ; 2005 Oct; 331(7522):966. PubMed ID: 16239707
    [No Abstract]   [Full Text] [Related]  

  • 60. Serious allergic reaction to administration of epirubicin.
    Oltmans R; van der Vegt SG
    Neth J Med; 2003 Jun; 61(6):226-7. PubMed ID: 12948166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.